Pharmacoeconomic review report Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)
Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once dail...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820269306719 |
| Sumario: | Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once daily. It is supplied as a solution in a pre-filled injector pen for subcutaneous administration in strengths of 0.05 mg/mL and 0.1 mg/mL, delivering 14 doses of 10 mcg per dose or 20 mcg per dose. The submitted price of lixisenatide is $56.98 per injector pen (regardless of strength) or $1,486 annually. |
|---|---|
| Descripción Física: | 1 online resource (28 pages) : illustrations |
| Bibliografía: | Includes bibliographical references. |
